News|Articles|March 15, 2016
- Pharmaceutical Technology-03-15-2016
- Volume 2016 eBook
- Issue 1
Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances
The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.
Advertisement
The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.
from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.
View other articles in the
Articles in this issue
about 10 years ago
Optimizing Tablet Compressionabout 10 years ago
Excipient Quality and Selectionabout 10 years ago
Filling the Analysis Gap in the Move to Continuous Processingabout 10 years ago
Modeling and Simulation Move Downstreamabout 10 years ago
Unifying Excipient Databasesabout 10 years ago
Establishing a New Performance Standard for HPMC CapsulesAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Big Pharma Is Betting Billions on Protein Degraders for Cancer
2
Delaware Governor Meyer on Drug Pricing, Reshoring, and National Security
3
Enhancing Clinical Data Infrastructure for AI Research: A Strategic Guide for Pharma Professionals
4
Renewing Prosaic Generics for Cancer Treatment
5